Search Medical Condition
Please enter condition
Please choose location from dropdown

Flemalles Haute, Belgium Clinical Trials

A listing of Flemalles Haute, Belgium clinical trials actively recruiting patients volunteers.

RESULTS

Found (163) clinical trials

Fabry Disease Registry

The Fabry Registry is an international program; in addition to the central contact information provided under the "Location" heading, patients may contact: In Asia-Pacific - Vivian Liu, +65-6431-2548, Vivian.liu@genzyme.com In Europe - +31-35-699-1232, europe@FabryRegistry.com In Latin America - +617-591-5500, help@FabryRegistry.com In North America - +617-591-5500, help@FabryRegistry.com

Phase N/A

3.03 miles

Learn More »

A Study of the Real-life Management of Psoriasis Patients Treated With Otezla (Apremilast) in Belgium

Patient care will follow routine clinical practice, involving regular follow-up visits, without any mandatory visit. In daily practice, patients are usually seen by their treating dermatologists every 3 months. In this study, patients will be followed-up for a least 6 months and at most 18 months after apremilast treatment initiation. ...

Phase N/A

3.03 miles

Learn More »

Ifosfamide and Doxorubicin Radiation Therapy and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma

OBJECTIVES: Primary - Determine survival rates (event-free survival and overall survival [OS]) and the pattern of treatment failure in patients with synovial sarcoma or adult-type soft tissue sarcoma treated with ifosfamide and doxorubicin hydrochloride, radiotherapy, and/or surgery. - Determine the role of ifosfamide and doxorubicin hydrochloride in improving the response ...

Phase

4.32 miles

Learn More »

Safety Pharmacokinetics Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)

Tolvaptan has been demonstrated to delay the decline of kidney function in adults with rapidly progressing ADPKD (CKD stages 1 to 3) as measured by estimated glomerular filtration rate (eGFR) and Total Kidney Volume (TKV). This trial will be the first trial of tolvaptan in children and adolescents with ADPKD. ...

Phase

4.32 miles

Learn More »

Clinical Safety & Efficacy of a New Infant Formula With Specific Medical Purpose Containing Human Milk Oligosaccharides

Infants with physician diagnosed CMPA, aged between birth and 6 months of age will take either the control or new test infant formula for 4 months and if judged suitable by physician, up to maximum of 12 months of age. Growth, adverse events, medication use and tolerance to formula will ...

Phase N/A

4.32 miles

Learn More »

Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 Years

This study evaluates the effect of different induction courses in children and adolescents with newly diagnosed acute myeloid leukemia. In the first course patients are randomised to receive either standard anthracycline therapy with mitoxantrone or experimental DaunoXome. In the second course patients are randomised between standard treatment with ADxE (cytarabine, ...

Phase

4.32 miles

Learn More »

High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)

In this protocol the term high-risk neuroblastoma refers to children with either disseminated disease (INSS stage 4: about 40 to 50% of all neuroblastoma) over the age of one or INSS stage 2 and 3 disease with amplification of the MycN proto-oncogene Between 10% and 20% of children with stage ...

Phase

4.32 miles

Learn More »

Long Term Safety Study of Orfadin Treatment in HT-1 Patients in Standard Clinical Care

The planned study is a non-interventional study that will look at the long-term safety of Orfadin treatment in patients suffering from hereditary tyrosinemia type 1. Orfadin will be used according to normal practice . There is an ongoing post-marketing surveillance (PMS) program to monitor hepatic, renal, hematological, neurological and ophthalmic ...

Phase N/A

4.32 miles

Learn More »

Tysabri Observational Program

TOP is an epidemiological observational study of participants receiving natalizumab, with each participant to be followed for up to 10 years. This study is designed to address the long-term safety profile and the long-term impact on disease activity and progression of natalizumab with marketed use, and the impact of treatment ...

Phase N/A

5.67 miles

Learn More »

Phase

5.67 miles

Learn More »